https://crstodayeurope.com/news/vision-ophthalmology-group-acquires-med-medical-products-gmbh/2479803/daily0.7https://crstodayeurope.com/news/silgan-dispensing-introduces-iridya-eye-dropper-to-ensure-accurate-doses-down-to-the-drop/2479804/daily0.7https://crstodayeurope.com/news/johnson-johnson-vision-launches-worldwide-campaign-to-spotlightsight-in-honor-of-world-sight-day/2479805/daily0.7https://crstodayeurope.com/news/optikon-introduces-r-evo-smart-for-cataract-and-retinal-surgery/2479806/daily0.7https://crstodayeurope.com/news/prac-recommends-restrictions-on-fluoroquinolone-quinolones/2479807/daily0.7https://crstodayeurope.com/news/placing-a-bypass-stent-during-cataract-surgery-cuts-need-for-glaucoma-eyedrops/2479808/daily0.7https://crstodayeurope.com/news/department-of-defense-grant-for-clinical-trial-of-stem-cell-therapy-for-eye-injuries/2479809/daily0.7https://crstodayeurope.com/news/new-display-design-could-make-lightweight-compact-smart-glasses-a-reality/2479811/daily0.7https://crstodayeurope.com/news/zeiss-receives-fda-approval-for-astigmatism-indication-for-relex-smile/2479812/daily0.7https://crstodayeurope.com/news/dynamin-binding-protein-linked-to-congenital-cataracts/2479813/daily0.7https://crstodayeurope.com/news/kala-pharmaceuticals-announces-financing-from-athyrium-capital-management-totaling-110-million/2479817/daily0.7https://crstodayeurope.com/news/ziemer-usa-sponsors-visionary-leader-award-at-owl-meeting/2479819/daily0.7https://crstodayeurope.com/news/the-refractive-surgery-council-rolls-out-new-rsc-verified-patient-education-program-for-surgeons/2479820/daily0.7https://crstodayeurope.com/news/alcon-introduces-enhanced-wavelight-refractive-suite/2479821/daily0.7https://crstodayeurope.com/news/eyevance-acquires-global-rights-to-persistent-corneal-epithelial-defect-treatment-nexagon/2479822/daily0.7https://crstodayeurope.com/news/donna-fishman-named-director-of-the-national-center-for-childrens-vision-and-eye-health-at-prevent-blindness/2479823/daily0.7https://crstodayeurope.com/news/visioneering-technologies-selects-corneal-lens-corporation-nz-and-contact-lens-centre-australia-to-distribute-naturalvue-brand-contact-lenses-in-anz/2479825/daily0.7https://crstodayeurope.com/news/aao-new-study-confirms-mediterranean-diet-prevents-a-leading-cause-of-blindness/2479827/daily0.7https://crstodayeurope.com/news/chiropractic-treatment-and-vision-loss-examining-the-connection/2479828/daily0.7https://crstodayeurope.com/news/eyepoint-pharmaceuticals-announces-proceeds-of-28-9-million-from-exercised-warrants/2479829/daily0.7https://crstodayeurope.com/news/the-vision-council-conducts-study-on-contact-lens-subscription-services/2479830/daily0.7https://crstodayeurope.com/news/omeros-announces-reinstatement-of-pass-through-status-for-omidria/2479831/daily0.7https://crstodayeurope.com/news/optovue-showcases-worlds-first-oct-angiography-metrics-and-non-contact-method-for-corneal-measurements-at-vision-expo-west/2479832/daily0.7https://crstodayeurope.com/news/novabay-pharmaceuticals-names-jack-mcgovern-interim-ceo/2479833/daily0.7https://crstodayeurope.com/news/veo-ophthalmics-launches-customflex-artificialiris-in-the-united-states/2479835/daily0.7https://crstodayeurope.com/news/nicox-and-fera-pharmaceuticals-to-focus-on-a-rare-disease-indication-for-naproxcinod/2479837/daily0.7https://crstodayeurope.com/news/peptidream-announces-drug-discovery-and-development-agreement-with-santen-pharmaceutical/2479839/daily0.7https://crstodayeurope.com/news/coopervision-releases-four-year-data-on-landmark-misight-1-day-contact-lens-study/2479840/daily0.7https://crstodayeurope.com/news/aldeyra-therapeutics-announces-positive-results-from-phase-2b-dry-eye-disease-clinical-trial/2479841/daily0.7https://crstodayeurope.com/news/national-industries-for-the-blind-announces-new-strategic-alliance/2479842/daily0.7https://crstodayeurope.com/news/ascrs-releases-preliminary-cypass-withdrawal-consensus-statement/2479843/daily0.7https://crstodayeurope.com/news/cms-proposes-to-eliminate-medicare-certification-requirements-for-comprehensive-hps-and-transfer-agreements-with-hospitals/2479844/daily0.7https://crstodayeurope.com/news/hoya-launches-4-in-1-multisert-preloaded-delivery-system-with-vivinex-iol/2479847/daily0.7https://crstodayeurope.com/news/neurolens-appoints-davis-corley-chief-executive-officer/2479848/daily0.7https://crstodayeurope.com/news/siteone-therapeutics-receives-nih-grant-to-support-the-development-of-novel-therapeutics-to-treat-ocular-pain/2479849/daily0.7https://crstodayeurope.com/news/novartis-to-cut-over-2000-jobs-in-switzerland-uk/2479850/daily0.7https://crstodayeurope.com/news/cigna-now-covering-avedros-fda-approved-cross-linking-procedure/2479851/daily0.7https://crstodayeurope.com/news/burnout-starts-early-especially-in-some-specialties/2483631/daily0.7https://crstodayeurope.com/news/heidelberg-engineering-announces-the-ce-marking-of-anterion/2479854/daily0.7https://crstodayeurope.com/news/johnson-johnson-vision-showcases-latest-clinical-data-and-eye-care-solutions-at-escrs/2479857/daily0.7https://crstodayeurope.com/news/new-10-year-warranty-for-haag-streit-slit-lamps/2479858/daily0.7https://crstodayeurope.com/news/zeiss-presents-integrated-data-driven-digital-solutions-at-escrs/2479859/daily0.7https://crstodayeurope.com/news/nidek-launches-the-gs-1-gonioscope/2479862/daily0.7https://crstodayeurope.com/news/schwind-announces-825000-treatments-performed-with-no-touch-eye-laser-treatment/2479865/daily0.7https://crstodayeurope.com/news/oculus-to-present-new-formulas-for-the-pentacam-axl-advanced-barrett-and-olsen-formulas/2479866/daily0.7https://crstodayeurope.com/news/iridex-announces-micropulse-treatment-symposium-at-escrs/2479868/daily0.7https://crstodayeurope.com/news/iot-launches-new-corporate-branding/2479870/daily0.7https://crstodayeurope.com/news/excel-lens-announces-ce-mark-approval-for-capsulaser-selective-laser-capsulotomy-slc-device/2479872/daily0.7https://crstodayeurope.com/news/allergan-announces-new-partnership-with-the-international-diabetes-federation/2479873/daily0.7https://crstodayeurope.com/news/coopervision-releases-4-year-data-on-landmark-misight-1-day-contact-lens-study/2479874/daily0.7https://crstodayeurope.com/news/zeiss-announces-1-5-million-smile-procedures-performed/2479875/daily0.7https://crstodayeurope.com/news/neurolens-appoints-thomas-j-chirillo-as-chief-commercial-officer/2479876/daily0.7https://crstodayeurope.com/news/fda-grants-lin-bioscience-rare-pediatric-disease-status-for-lbs-008-to-treat-stargardt-disease/2479877/daily0.7https://crstodayeurope.com/news/katena-products-announces-launch-of-the-new-katena-com/2479878/daily0.7https://crstodayeurope.com/news/heidelberg-engineering-oct-angiography-module-now-available-in-the-united-states/2479879/daily0.7https://crstodayeurope.com/news/alcon-launches-alcon-experience-academy-online-portal-for-training-and-education-for-eye-care-professionals/2479881/daily0.7https://crstodayeurope.com/news/chinese-regulators-clear-takedas-62-billion-takeover-of-shire/2479882/daily0.7https://crstodayeurope.com/news/diopsys-highlights-educational-initiatives-for-escrs-2018/2479883/daily0.7https://crstodayeurope.com/news/quantel-medical-launches-absolu-ultrasound-platform/2479884/daily0.7https://crstodayeurope.com/news/market-scope-ophthalmic-laser-market-expected-to-total-400-million-in-2018/2479885/daily0.7https://crstodayeurope.com/news/sun-pharma-and-sparc-announced-fda-approval-of-xelpros-to-treat-open-angle-glaucoma-or-ocular-hypertension/2479886/daily0.7https://crstodayeurope.com/news/ziemer-announces-to-implement-low-energy-lenticule-extraction-applications-to-its-femtosecond-laser-platform/2479888/daily0.7https://crstodayeurope.com/news/first-patient-treated-in-multicenter-trial-examining-allotex-transform-allogenic-refractive-lenticules-for-treatment-of-presbyopia/2479889/daily0.7https://crstodayeurope.com/news/staar-surgical-announces-fda-approval-of-the-visian-toric-icl-for-the-correction-of-myopia-with-astigmatism/2479890/daily0.7https://crstodayeurope.com/news/sightlife-women-advocates-head-to-nepal-to-support-blindness-prevention-program/2479891/daily0.7https://crstodayeurope.com/news/report-takeda-may-sell-shire-assets-to-reduce-debt-following-62-billion-purchase/2479892/daily0.7https://crstodayeurope.com/news/alcon-introduces-new-air-optix-plus-hydraglyde-multifocal-contact-lenses/2479894/daily0.7https://crstodayeurope.com/news/alcon-adds-new-ultraviolet-absorbing-only-iol-options-to-its-acrysof-portfolio/2479895/daily0.7https://crstodayeurope.com/news/oculus-announces-release-of-smartfield-smart-compact-perimeter/2479897/daily0.7https://crstodayeurope.com/news/apellis-announces-first-patient-dosed-in-its-phase-3-clinical-program-for-apl-2-in-patients-with-geographic-atrophy/2479898/daily0.7https://crstodayeurope.com/news/sightmd-24-location-ophthalmology-group-and-chicago-pacific-founders-set-partnership/2479899/daily0.7https://crstodayeurope.com/news/new-joystick-for-the-keratograph-5m-with-release-function/2479900/daily0.7https://crstodayeurope.com/news/alcon-to-move-headquarters-from-texas-to-switzerland-following-proposed-spinoff-from-novartis/2479901/daily0.7https://crstodayeurope.com/news/eyevance-pharmaceuticals-acquires-freshkote-lubricant-eye-drop-family-of-products/2483632/daily0.7https://crstodayeurope.com/news/clearside-biomedical-to-participate-in-2018-janney-healthcare-conference/2483633/daily0.7https://crstodayeurope.com/news/topcon-announces-appointment-of-gregory-hoffmeyer-to-director-of-oct-clinical-sales/2479902/daily0.7https://crstodayeurope.com/news/orbis-and-visulytix-unveil-collaboration-to-integrate-ai-into-global-eye-health-efforts/2479903/daily0.7https://crstodayeurope.com/news/oxurion-nv-announces-new-nyse-euronext-brussels-stock-ticker-oxur-and-launch-of-new-website/2479904/daily0.7https://crstodayeurope.com/news/innovative-pay-it-forward-training-program-for-specialty-eye-surgeons/2479905/daily0.7https://crstodayeurope.com/news/eyesouth-expands-into-south-florida-through-affiliation-with-florida-eye-microsurgical-institute/2479907/daily0.7https://crstodayeurope.com/news/endothelial-cell-density-after-iris-fixated-phakic-iol/2479908/daily0.7https://crstodayeurope.com/news/gaming-for-an-independent-life-hope-for-visually-impaired-children-with-new-computer-game/2479909/daily0.7https://crstodayeurope.com/news/contact-lens-companies-seek-summary-judgment-in-lawsuit-over-minimum-pricing/2479910/daily0.7https://crstodayeurope.com/news/uk-calls-on-drugmakers-to-stockpile-6-week-supply-of-medicines-to-cope-with-no-deal-brexit/2479911/daily0.7https://crstodayeurope.com/news/adolescents-with-strabismus-more-likely-to-have-psychological-problems/2479912/daily0.7https://crstodayeurope.com/news/kala-pharmaceuticals-announces-fda-approval-of-inveltys-for-the-treatment-of-postoperative-inflammation-and-pain-following-ocular-surgery/2479913/daily0.7https://crstodayeurope.com/news/devices-to-expand-role-of-surgery-in-glaucoma-treatment/2479914/daily0.7https://crstodayeurope.com/news/open-angle-glaucoma-in-one-eye-likely-to-develop-in-the-other/2479915/daily0.7https://crstodayeurope.com/news/dompe-receives-fda-approval-of-oxervate-a-first-in-class-treatment-of-neurotrophic-keratitis/2479916/daily0.7https://crstodayeurope.com/news/fda-approves-first-drug-for-neurotrophic-keratitis/2479917/daily0.7https://crstodayeurope.com/news/lenstec-completes-enrollment-of-fda-trial-for-sbl-3-iol/2479919/daily0.7https://crstodayeurope.com/news/staying-fit-might-cut-glaucoma-risk/2479921/daily0.7https://crstodayeurope.com/news/joseph-gordon-named-us-president-of-bausch-lomb/2479922/daily0.7https://crstodayeurope.com/news/eyeque-expands-vision-monitoring-for-consumers-adding-color-and-contrast-sensitivity-tests-to-insight-vision-screener/2479923/daily0.7https://crstodayeurope.com/news/cdc-launches-the-nations-first-vision-and-eye-health-surveillance-system/2479924/daily0.7https://crstodayeurope.com/news/allegro-prepares-to-take-lead-compound-risuteganib-to-phase-3-appoints-new-ceo/2479926/daily0.7https://crstodayeurope.com/news/eyegate-announces-enrollment-of-first-patient-in-prk-pilot-study/2479928/daily0.7https://crstodayeurope.com/news/university-of-toledo-chemists-discover-how-blue-light-speeds-blindness/2479929/daily0.7https://crstodayeurope.com/news/roches-genentech-unit-to-cut-223-jobs-in-us/2479930/daily0.7https://crstodayeurope.com/news/topcon-announces-date-for-3rd-annual-issoct-conference/2479931/daily0.7https://crstodayeurope.com/news/t-cell-immune-responses-drive-neurodegeneration-in-glaucoma/2479933/daily0.7https://crstodayeurope.com/news/artificial-intelligence-in-ophthalmology-a-brave-new-world-coming/2479934/daily0.7https://crstodayeurope.com/news/artificial-iris-of-humanoptics-receives-fda-approval/2479935/daily0.7https://crstodayeurope.com/news/a-contact-lens-was-embedded-in-womans-eyelid-for-28-years/2479936/daily0.7https://crstodayeurope.com/news/bioaxone-biosciences-scientific-advisory-board-member-mark-bear-phd-receives-500000-beckman-argyros-vision-research-award/2479937/daily0.7https://crstodayeurope.com/news/sun-pharma-announces-fda-approval-of-cequa-to-treat-dry-eye-disease/2479938/daily0.7https://crstodayeurope.com/news/unitedhealthcare-eye-care-program-aims-to-give-children-access-to-comprehensive-eye-exams-and-glasses/2479940/daily0.7https://crstodayeurope.com/news/glasses-may-boost-productivity-for-rural-workers/2479941/daily0.7https://crstodayeurope.com/news/aerie-pharmaceuticals-reports-topline-result-from-rhopressa-mechanism-of-action-study/2479942/daily0.7https://crstodayeurope.com/news/breakthrough-in-ai-technology-to-improve-care-for-patients/2479943/daily0.7https://crstodayeurope.com/news/study-suggests-glaucoma-may-be-an-autoimmune-disease/2479944/daily0.7https://crstodayeurope.com/news/bascom-palmer-eye-institute-ranked-nations-no-1-in-ophthalmology-for-17th-time/2479945/daily0.7https://crstodayeurope.com/news/eyenovias-eyn-pg21-trial-evaluating-high-precision-microdose-of-latanoprost-demonstrates-iop-lowering-and-patient-usability/2479947/daily0.7https://crstodayeurope.com/news/astellas-announces-acquisition-of-quethera-maker-of-gene-therapy-program-for-glaucoma/2479949/daily0.7https://crstodayeurope.com/news/ivantis-receives-fda-approval-for-the-hydrus-microstent-device-for-minimally-invasive-glaucoma-surgery-migs/2479950/daily0.7https://crstodayeurope.com/news/australian-research-lifts-the-lid-on-lipids-to-prevent-dry-eye/2479951/daily0.7https://crstodayeurope.com/news/eye-conditions-provide-new-lens-for-screening-for-alzheimer-disease/2479952/daily0.7https://crstodayeurope.com/news/eyevensys-appoints-new-board-member-gerald-cagle/2483634/daily0.7https://crstodayeurope.com/news/web-vision-technologies-receives-grants-to-develop-vision-testing-devices-for-nasa/2479953/daily0.7https://crstodayeurope.com/news/regenxbio-reports-second-quarter-2018-financial-and-operating-results-and-interim-data-from-ongoing-clinical-trials/2479954/daily0.7https://crstodayeurope.com/news/aerie-pharmaceuticals-reports-second-quarter-2018-financial-results-and-provides-business-update/2483635/daily0.7https://crstodayeurope.com/news/one-in-7-babies-exposed-to-zika-have-health-problems-cdc-says/2483636/daily0.7https://crstodayeurope.com/news/eyeque-hires-datta-nadkarni-as-chief-marketing-officer-to-strengthen-leadership-team/2483637/daily0.7https://crstodayeurope.com/news/bsm-consulting-hires-mark-rosenberg-to-expand-depth-of-client-services/2483638/daily0.7https://crstodayeurope.com/news/trabeculectomy-outcomes-different-for-patients-of-african-vs-european-descent/2479955/daily0.7https://crstodayeurope.com/news/glaukos-announces-pharmaceutical-development-agreement-with-d-western-therapeutics-institute/2479956/daily0.7https://crstodayeurope.com/news/eye-health-america-acquires-montgomery-riddle-eyecare-in-south-carolina/2479957/daily0.7https://crstodayeurope.com/news/gene-mutation-found-in-aqueous-humor-may-detect-vitreoretinal-lymphoma/2479958/daily0.7https://crstodayeurope.com/news/fda-finalizes-guidance-on-integrating-ehrs-into-clinical-trials/2479961/daily0.7https://crstodayeurope.com/news/nicox-initiates-phase-2-study-of-ncx-470-in-open-angle-glaucoma-and-ocular-hypertension/2479962/daily0.7https://crstodayeurope.com/news/ocutech-introduces-new-ves-falcon-autofocus-bioptic-telescope/2479963/daily0.7https://crstodayeurope.com/news/international-sports-vision-association-announces-appointment-of-gary-esterow-as-executive-director/2479964/daily0.7https://crstodayeurope.com/news/guardion-health-sciences-receives-methods-patents-to-standardize-vision-testing/2479965/daily0.7https://crstodayeurope.com/news/aerie-pharmaceuticals-and-dsm-biomedical-expand-collaboration-agreement-focused-on-novel-drug-delivery-technology-in-ophthalmology/2479966/daily0.7https://crstodayeurope.com/news/imprimis-announces-clinical-trial-for-dropless-trimoxi-formulation-in-canada/2479968/daily0.7https://crstodayeurope.com/news/eyepoint-pharmaceuticals-appoints-david-price-as-chief-financial-officer/2479969/daily0.7https://crstodayeurope.com/news/radiancetx-raises-1-million-first-tranche-to-develop-novel-glaucoma-therapy/2479970/daily0.7https://crstodayeurope.com/news/glaucoma-research-foundation-grant-leads-to-breakthrough-in-neuron-regeneration/2479971/daily0.7https://crstodayeurope.com/news/aao-launches-new-scientific-journal-dedicated-to-glaucoma-research/2479972/daily0.7https://crstodayeurope.com/news/kala-pharmaceuticals-announces-dosing-of-first-patient-in-phase-3-stride-3-trial-of-kpi-121-0-25-in-patients-with-dry-eye-disease/2479973/daily0.7https://crstodayeurope.com/news/thomas-burns-ceo-of-glaukos-joins-avedros-board-of-directors/2479974/daily0.7https://crstodayeurope.com/news/aussie-researchers-identify-new-genetic-markers-for-glaucoma/2479975/daily0.7https://crstodayeurope.com/news/unsafe-ocular-stem-cell-treatments-prevalent/2479976/daily0.7https://crstodayeurope.com/news/visual-function-problems-may-be-more-common-in-children-with-dyslexia/2479977/daily0.7https://crstodayeurope.com/news/presbyopia-therapies-announces-primary-safety-and-efficacy-resutls-in-phase-2b-study-of-topical-presbyopia-treatment/2479978/daily0.7https://crstodayeurope.com/news/allergan-lifts-earnings-target-says-no-drug-price-hikes-this-year/2479979/daily0.7https://crstodayeurope.com/news/family-income-ethnicity-and-health-literacy-may-affect-childrens-vision-eye-care-access/2479982/daily0.7https://crstodayeurope.com/news/eyepoint-pharmaceuticals-announces-presentation-of-data-highlighting-yutiq-for-posterior-segment-uveitis/2479984/daily0.7https://crstodayeurope.com/news/surgeons-from-vance-thompson-vision-make-impact-with-mission-trip-to-honduras/2479985/daily0.7https://crstodayeurope.com/news/rayners-new-uk-based-manufacturing-facility-receives-fda-approval/2479988/daily0.7https://crstodayeurope.com/news/q-biomed-extends-its-exclusive-option-agreement-with-washington-university-for-glaucoma-detection-biomarker/2479989/daily0.7https://crstodayeurope.com/news/eton-pharma-reports-positive-topline-results-from-phase-3-trial-of-em-100/2479990/daily0.7https://crstodayeurope.com/news/topcon-announces-release-of-augmented-reality-ar-app/2479991/daily0.7https://crstodayeurope.com/news/state-strips-ex-usc-medical-school-dean-of-license-citing-an-appalling-lack-of-judgment/2479992/daily0.7https://crstodayeurope.com/news/omeros-corporation-initiates-sales-of-omidria-in-europe/2479997/daily0.7https://crstodayeurope.com/news/aerie-pharmaceuticals-announces-early-notification-of-fda-acceptance-of-nda-submission-for-roclatan/2479999/daily0.7https://crstodayeurope.com/news/u-s-court-rejects-allergan-bid-to-shield-patents-through-tribe-deal/2480000/daily0.7https://crstodayeurope.com/news/alcon-introduces-ngenuity-3d-visualization-system-with-datafusion-vitreoretinal-surgery-device/2480001/daily0.7https://crstodayeurope.com/news/pattern-scanning-laser-trabeculoplasty-program-obtains-fda-clearance-for-the-pascal-synthesis-and-twinstar/2480002/daily0.7https://crstodayeurope.com/news/report-highlights-new-health-concern-for-rohingya-refugees-eye-health-needed-treatment-for-preventable-blindness/2480003/daily0.7https://crstodayeurope.com/news/heidelberg-engineering-announces-leadership-changes/2480004/daily0.7https://crstodayeurope.com/news/us-to-develop-drug-import-policy-aimed-at-countering-price-hikes/2480005/daily0.7https://crstodayeurope.com/news/new-studies-prove-kamra-inlay-is-a-safe-and-effective-treatment-for-presbyopia/2480006/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-announces-fda-acceptance-of-nda-resubmission-for-dextenza/2480009/daily0.7https://crstodayeurope.com/news/fda-releases-action-plan-to-speed-up-market-entry-for-biosimilars/2480010/daily0.7https://crstodayeurope.com/news/alzheimers-therapeutics-research-leader-dr-roy-twyman-joins-neurovision-imaging-board/2480013/daily0.7https://crstodayeurope.com/news/blephex-names-fred-ellis-ceo/2480014/daily0.7https://crstodayeurope.com/news/sheraz-daya-md-introduces-the-daya-icl-forceps/2480015/daily0.7https://crstodayeurope.com/news/valeant-now-officially-bausch-health-companies-begins-trading-as-bhc/2480016/daily0.7https://crstodayeurope.com/news/lensgen-announces-funding-and-patent-success/2480017/daily0.7https://crstodayeurope.com/news/rgn-259-tceb24-improves-clinically-important-dry-eye-efficacies-in-comparison-with-prescription-drugs/2480019/daily0.7https://crstodayeurope.com/news/practice-hospital-consolidation-increasing-for-many-specialties/2480021/daily0.7https://crstodayeurope.com/news/novartis-disputes-findings-of-report-from-us-senators-claiming-more-extensive-links-with-trump-lawyer/2483639/daily0.7https://crstodayeurope.com/news/patients-with-down-syndrome-may-have-keratoconus-like-corneas/2480022/daily0.7https://crstodayeurope.com/news/zeiss-names-news-chief-financial-officer/2480025/daily0.7https://crstodayeurope.com/news/lightmed-announces-new-office-location-in-caesarea-israel/2480027/daily0.7https://crstodayeurope.com/news/novartis-exits-antibacterial-antiviral-research/2480028/daily0.7https://crstodayeurope.com/news/oyster-point-pharma-announces-positive-results-from-phase-2-clinical-trial-of-investigational-treatment-for-dry-eye-disease/2480029/daily0.7https://crstodayeurope.com/news/some-companies-cancel-reduce-planned-price-hikes-amid-continued-pressure-over-us-drug-costs-report/2480031/daily0.7https://crstodayeurope.com/news/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-for-posterior-segment-uveitis-to-be-presented-at-asrs/2480032/daily0.7https://crstodayeurope.com/news/iridex-reaches-milestone-of-1000th-cyclo-g6-system-shipped/2480033/daily0.7https://crstodayeurope.com/news/allergan-launches-new-refresh-repair-lubricant-eye-drops/2480034/daily0.7https://crstodayeurope.com/news/takeda-receives-clearance-from-the-ftc-for-the-proposed-acquisition-of-shire/2480035/daily0.7https://crstodayeurope.com/news/bausch-lomb-announces-fda-filing-acceptance-for-loteprednol-etabonate-ophthalmic-gel/2480037/daily0.7https://crstodayeurope.com/news/eyenovia-appoints-michael-rowe-as-vice-president-of-marketing/2480038/daily0.7https://crstodayeurope.com/news/mpod-measurement-earns-american-medical-association-cpt-iii-code/2480039/daily0.7https://crstodayeurope.com/news/sue-anschutz-rodgers-eye-center-a-highly-visible-legacy-of-longstanding-philanthropic-partnership/2480040/daily0.7https://crstodayeurope.com/news/eyesouth-partners-develops-of-physician-advisory-board/2480041/daily0.7https://crstodayeurope.com/news/study-combined-cataract-surgery-ups-postop-endophthalmitis-risk/2480042/daily0.7https://crstodayeurope.com/news/katena-products-announces-the-acquisition-of-blink-medical/2480044/daily0.7https://crstodayeurope.com/news/wills-eye-hospital-announces-5-million-gift-for-vision-research/2480046/daily0.7https://crstodayeurope.com/news/association-of-optometrists-and-seco-international-announce-partnership-with-armed-forces-optometric-society-for-therapeutics-london-2018/2480047/daily0.7https://crstodayeurope.com/news/cataract-surgery-tied-to-lower-risk-of-car-crashes/2480048/daily0.7https://crstodayeurope.com/news/abom-announces-sales-alliance-with-essilor-prescription-safety-eyewear-for-rx-with-advanced-anti-fog-technology/2480049/daily0.7https://crstodayeurope.com/news/oculus-incorporates-oculus-brasil-in-sao-paulo/2480050/daily0.7https://crstodayeurope.com/news/prevent-blindness-to-hold-thirteenth-annual-eyes-on-capitol-hill-advocacy-event/2480051/daily0.7https://crstodayeurope.com/news/novartis-chairman-says-alcon-worth-20-billion-30-billion-finanz-und-wirtschaft/2480052/daily0.7https://crstodayeurope.com/news/ocugen-initiates-phase-3-clinical-trial-of-ocu300-for-the-treatment-of-ocular-graft-versus-host-disease/2480053/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-announces-nda-resubmission-of-dextenza/2480054/daily0.7https://crstodayeurope.com/news/novartis-announces-intention-to-spinoff-alcon-and-launch-a-5-billion-share-buyback/2480055/daily0.7https://crstodayeurope.com/news/former-pg-and-cincinnati-childrens-executive-katherine-overbey-joins-onesight-as-president-and-executive-director/2480057/daily0.7https://crstodayeurope.com/news/oyster-point-pharma-gets-green-light-from-fda-to-proceed-with-clinical-development-of-dry-eye-treatment/2480060/daily0.7https://crstodayeurope.com/news/neuro-optometric-rehabilitation-association-nora-launches-redesigned-website-accepts-award-nominations/2480061/daily0.7https://crstodayeurope.com/news/market-scope-oct-market-to-generate-632-million-in-revenues-in-2018/2480062/daily0.7https://crstodayeurope.com/news/thrombogenics-plans-name-change-to-oxurion/2480064/daily0.7https://crstodayeurope.com/news/aerpio-pharmaceuticals-announces-uplisting-to-nasdaq-capital-market-and-pricing-of-45-million-public-offering-of-common-stock/2480066/daily0.7https://crstodayeurope.com/news/market-scope-new-products-poised-to-drive-glaucoma-pharma-market-to-6-6-billion-by-2023/2480067/daily0.7https://crstodayeurope.com/news/staar-surgical-and-kobe-kanagawa-eye-clinic-in-japan-announce-strategic-cooperation-agreement/2480068/daily0.7https://crstodayeurope.com/news/iridex-announces-multiple-studies-of-micropulse-laser-therapy-published-at-woc/2480069/daily0.7https://crstodayeurope.com/news/eyepoint-pharmaceuticals-announces-stockholder-approval-of-second-tranche-of-capital-financing/2480070/daily0.7https://crstodayeurope.com/news/silicon-valley-eye-doctor-named-optometrist-of-the-year-by-american-optometric-association/2480071/daily0.7https://crstodayeurope.com/news/intraocular-robotic-surgery-feasible-first-in-human-study/2480072/daily0.7https://crstodayeurope.com/news/glaukos-announces-fda-approval-for-the-istent-inject-trabecular-micro-bypass-system/2480073/daily0.7https://crstodayeurope.com/news/zeiss-unveils-next-generation-of-ophthalmic-laser-visulas-green-at-world-ophthalmology-congress/2480074/daily0.7https://crstodayeurope.com/news/us-proposes-reorganization-under-which-fda-would-be-renamed-federal-drug-administration/2483640/daily0.7https://crstodayeurope.com/news/nusight-medical-launches-nulids-for-the-treatment-of-dry-eye/2480078/daily0.7https://crstodayeurope.com/news/bio-tissue-highlights-publication-of-dream-study/2480079/daily0.7https://crstodayeurope.com/news/staar-surgical-announces-resolution-of-fda-warning-letter/2480080/daily0.7https://crstodayeurope.com/news/kala-pharmaceuticals-announces-update-to-kpi-121-0-25-development-plan/2480081/daily0.7https://crstodayeurope.com/news/avedro-announces-enrollment-of-first-patient-in-phase-3-epi-on-corneal-cross-linking-trial/2480082/daily0.7https://crstodayeurope.com/news/american-vision-partners-acquires-miles-eye-center/2480084/daily0.7https://crstodayeurope.com/news/american-academy-of-ophthalmology-reiterates-long-standing-guidance-on-lasik-patient-education/2480085/daily0.7https://crstodayeurope.com/news/foundation-fighting-blindness-launches-the-stargardt-disease-natural-history-study/2480086/daily0.7https://crstodayeurope.com/news/allergan-announces-former-abbott-executive-to-join-board-of-directors-as-part-of-refreshment-process/2480087/daily0.7https://crstodayeurope.com/news/optovue-announces-expanded-fda-clearance-of-epithelial-thickness-mapping/2480088/daily0.7https://crstodayeurope.com/news/bausch-lomb-launches-soothe-xtra-protection-preservative-free-lubricant-eye-drops/2480089/daily0.7https://crstodayeurope.com/news/dr-robert-ritch-forum-on-medicine-of-the-future-at-world-ophthalmology-congress-2018/2480090/daily0.7https://crstodayeurope.com/news/researchers-find-novel-structure-in-the-antennae-of-light-sensing-neurons/2480091/daily0.7https://crstodayeurope.com/news/trump-health-chief-renews-call-to-end-key-drug-pricing-tactic/2480094/daily0.7https://crstodayeurope.com/news/allergan-announces-positive-topline-phase-3-clinical-data-for-bimatoprost-sr-implant/2480095/daily0.7https://crstodayeurope.com/news/shire-launches-screen-responsibly-initiative-to-prioritize-eye-health-in-a-screen-saturated-world/2480096/daily0.7https://crstodayeurope.com/news/synergeyes-and-brien-holden-vision-institute-join-forces-for-specialty-contact-lens-development/2480098/daily0.7https://crstodayeurope.com/news/helpmesee-eye-surgery-simulator-demonstrations-scheduled-for-the-2018-world-ophthalmology-conference-in-barcelona/2480099/daily0.7https://crstodayeurope.com/news/cms-issues-preliminary-decision-on-unique-j-code-for-avedro-photrexa-drug-formulations/2480101/daily0.7https://crstodayeurope.com/news/quantel-medical-creates-a-new-subsidiary-in-poland/2480102/daily0.7https://crstodayeurope.com/news/new-data-physicians-experience-highest-suicide-rate-of-any-profession/2480104/daily0.7https://crstodayeurope.com/news/alcon-launches-social-media-campaign-to-educate-cataract-patients-on-treatment-options/2480106/daily0.7https://crstodayeurope.com/news/eyesouth-announces-strategic-partnership-with-south-georgia-north-florida-eye-partners/2480107/daily0.7https://crstodayeurope.com/news/ophthalmologists-issue-eye-safety-warning-ahead-of-fireworks-severy-year-about-10000-people-are-rushed-to-the-emergency-department-for-fireworks-injuries-ophthalmologists-physicians-who-s/2480108/daily0.7https://crstodayeurope.com/news/eyenovia-receives-notices-of-allowance-from-uspto-on-two-additional-patent-applications-for-ophthalmic-drug-delivery/2480109/daily0.7https://crstodayeurope.com/news/ophthalmic-or-microscope-market-to-see-more-than-6-percent-growth-over-next-five-years/2480110/daily0.7https://crstodayeurope.com/news/alcon-launches-new-multifocal-advertising-campaign-to-increase-awareness-of-contact-lens-options/2480111/daily0.7https://crstodayeurope.com/news/coburn-technologies-announces-new-location-for-corporate-headquarters/2480113/daily0.7https://crstodayeurope.com/news/ultrasonic-phaco-remains-dominant-but-new-technologies-ready-to-challenge/2480114/daily0.7https://crstodayeurope.com/news/group-of-takeda-shareholders-call-proposed-shire-purchase-height-of-madness/2480115/daily0.7https://crstodayeurope.com/news/allergan-shareholders-urge-company-to-overhaul-management-structure-split-role-of-chairman-and-ceo/2480116/daily0.7https://crstodayeurope.com/news/nicox-announces-research-collaboration-on-novel-ophthalmic-therapeutics-with-ironwood-pharmaceuticals/2480117/daily0.7https://crstodayeurope.com/news/chinese-researchers-use-waste-corneal-lenses-to-treat-eye-disease/2480118/daily0.7https://crstodayeurope.com/news/orasis-pharmaceuticals-closes-13-million-series-b-financing/2480119/daily0.7https://crstodayeurope.com/news/fda-commissioner-scott-gottlieb-provides-statement-on-proposed-modernization-of-fdas-drug-review-office/2480120/daily0.7https://crstodayeurope.com/news/bausch-lomb-enrolls-first-patient-in-envista-mx60ef-trifocal-iol-clinical-trial/2480122/daily0.7https://crstodayeurope.com/news/keck-medicine-of-usc-to-open-new-ambulatory-clinic-in-southern-californias-san-gabriel-valley/2480124/daily0.7https://crstodayeurope.com/news/caution-needed-with-artificial-intelligence-in-medicine-experts-warn/2480125/daily0.7https://crstodayeurope.com/news/fda-approves-first-artificial-iris/2480126/daily0.7https://crstodayeurope.com/news/ntc-to-strengthen-its-ophthalmology-portfolio-through-the-acquisition-of-ocular-antibiotic-products/2480127/daily0.7https://crstodayeurope.com/news/miracles-in-sight-seeks-to-expand-adoption-of-innovative-surgery-with-prepared-dmek-grafts/2480128/daily0.7https://crstodayeurope.com/news/trump-says-drug-companies-to-unveil-price-cuts-in-two-weeks/2480129/daily0.7https://crstodayeurope.com/news/allergan-plans-sales-of-womens-health-infectious-disease-units/2480131/daily0.7https://crstodayeurope.com/news/first-human-corneas-have-been-3d-printed-by-scientists-at-newcastle-university/2480132/daily0.7https://crstodayeurope.com/news/study-examines-imprimisrxs-dropless-steroid-and-antibiotic-intravitreal-injection/2480133/daily0.7https://crstodayeurope.com/news/cincinnati-eye-institute-launches-cei-vision-partners/2480134/daily0.7https://crstodayeurope.com/news/optovue-announces-retirement-of-industry-veteran-john-hawley/2480137/daily0.7https://crstodayeurope.com/news/white-light-exposure-suppresses-melatonin-secretion-in-many-blind-people/2480138/daily0.7https://crstodayeurope.com/news/new-type-of-treatable-vertigo-identified/2480140/daily0.7https://crstodayeurope.com/news/rayner-receives-ce-mark-for-its-hydrophobic-fully-preloaded-iol-injection-system/2480142/daily0.7https://crstodayeurope.com/news/wize-pharma-announces-presentation-of-new-data-on-lo2a-in-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogrens-syndrome/2480143/daily0.7https://crstodayeurope.com/news/gene-therapies-that-could-transform-diseases-get-easier-fda-path/2480144/daily0.7https://crstodayeurope.com/news/tear-film-innovations-completes-8-5-million-series-b-funding/2480145/daily0.7https://crstodayeurope.com/news/researchers-identify-genetic-variants-that-may-predict-glaucoma-risk/2480146/daily0.7https://crstodayeurope.com/news/ex-valeant-executive-guilty-of-taking-pharmacy-ceos-bribe/2480147/daily0.7https://crstodayeurope.com/news/aerie-submits-new-drug-application-to-fda-for-roclatan/2480148/daily0.7https://crstodayeurope.com/news/first-series-c-round-closing-for-medical-device-company-implandata-ophthalmic-products/2480150/daily0.7https://crstodayeurope.com/news/president-trump-outlines-plan-to-lower-drug-costs/2480151/daily0.7https://crstodayeurope.com/news/american-academy-of-optometry-launches-academy-online-an-online-ce-platform/2480153/daily0.7https://crstodayeurope.com/news/novartis-ceo-says-drugmakers-deal-with-trump-lawyer-was-a-mistake/2480155/daily0.7https://crstodayeurope.com/news/study-compares-the-accuracy-of-subjective-refraction-using-a-vmax-visions-vasr-vs-traditional-refraction/2480157/daily0.7https://crstodayeurope.com/news/kala-pharmaceuticals-strengthens-commercial-organization-in-preparation-for-first-product-launch/2480159/daily0.7https://crstodayeurope.com/news/free-cataract-removal-surgeries-for-those-in-need/2480160/daily0.7https://crstodayeurope.com/news/eye-health-america-appoints-cathleen-mccabe-md-as-chief-medical-officer/2480162/daily0.7https://crstodayeurope.com/news/bausch-lomb-initiates-clinical-trial-evaluating-new-ophthalmic-viscosurgical-device/2480163/daily0.7https://crstodayeurope.com/news/layerbio-awarded-1-2-million-from-nih-to-develop-sustained-release-glaucoma-drug/2480164/daily0.7https://crstodayeurope.com/news/valeant-will-become-bausch-health-companies-inc/2480165/daily0.7https://crstodayeurope.com/news/takeda-reaches-deal-to-buy-shire-for-around-62-billion/2480166/daily0.7https://crstodayeurope.com/news/takeda-nears-deal-to-buy-shire-in-its-biggest-purchase/2480167/daily0.7https://crstodayeurope.com/news/alcon-cares-project-100-commits-to-reducing-cataract-blindness-globally/2480168/daily0.7https://crstodayeurope.com/news/diopsys-study-highlights-the-important-role-of-perg-in-evaluation-of-manifest-and-suspected-glaucoma/2480170/daily0.7https://crstodayeurope.com/news/hoya-achieves-ce-mark-for-4-in-1-multisert-preloaded-delivery-system-with-vivinex-iol/2480171/daily0.7https://crstodayeurope.com/news/sylentis-announces-new-data-on-the-treatment-of-allergic-conjunctivitis/2480172/daily0.7https://crstodayeurope.com/news/regentree-presents-results-of-a-comparison-study-of-rgn-259-and-approved-prescription-drugs-for-dry-eye-syndrome-in-a-mouse-model-at-arvo/2480176/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-announces-treatment-of-first-patient-in-phase-1-clinical-trial-of-otx-tic-for-the-treatment-of-glaucoma-and-ocular-hypertension/2480177/daily0.7https://crstodayeurope.com/news/sylentis-announces-the-clinical-results-of-tivanisiran-for-the-treatment-of-dry-eye-syndrome/2480178/daily0.7https://crstodayeurope.com/news/nicox-presents-scientific-data-for-ncx-667-at-arvo/2480179/daily0.7https://crstodayeurope.com/news/owl-advancing-diversity-in-leadership-appoints-new-executive-director-gaynor-fries/2480180/daily0.7https://crstodayeurope.com/news/visulytixs-ai-tool-equivalent-to-human-experts-in-glaucoma-detection/2480181/daily0.7https://crstodayeurope.com/news/octane-partners-with-the-cedars-aspens-to-enhance-offerings/2480182/daily0.7https://crstodayeurope.com/news/iridex-announces-increase-in-micropulse-visibility-at-arvo/2480183/daily0.7https://crstodayeurope.com/news/regentree-presents-results-of-a-comparison-study-of-rgn-259-and-approved-prescription-drugs-for-dry-eye-syndrome/2480185/daily0.7https://crstodayeurope.com/news/glaucoma-research-foundation-speeds-search-for-a-cure/2480187/daily0.7https://crstodayeurope.com/news/avedro-announces-25-million-in-funding-to-fuel-innovation-and-commercial-growth/2480188/daily0.7https://crstodayeurope.com/news/vance-thompson-vision-announces-new-clinic-and-lasik-and-cataract-center-in-omaha/2480189/daily0.7